Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- All-Case PMS Requirement Lifted for Lenvima’s Thyroid Cancer Use
December 9, 2019
- Japan Ethical Drug Sales Up 1.7% in October: Crecon
December 9, 2019
- Wholesalers’ Bid-Rigging Scandal Might Have Been Exposed via Leniency Program, Further Cases Could Be Laid Bare: Lawyer
December 6, 2019
- Mochida, Idorsia Hook Up on Insomnia Drug in Japan
December 6, 2019
- Fujifilm’s US Bioscience Site Now Up and Running
December 6, 2019
- Daiichi Sankyo Reps Continue Heavy Pitches for Tarlige in September: Impact Track
December 6, 2019
- Keytruda Remains No. 1 in November Japan Drug Ranking: Encise
December 6, 2019
- Boston Biomedical Ties Up with 3 Institutions in Oncology Research
December 5, 2019
- With Audentes Buyout, Astellas Poised to Position “Genetic Regulation” as 5th Biz Pillar
December 4, 2019
- Original Maker Recalls Nizatidine over Carcinogen Risks
December 4, 2019
- Vyvanse Now Available in Japan 6 Months after Listing
December 4, 2019
- Astellas, Seattle Genetics Join Hands with US Merck for ADC/Keytruda Combo
December 4, 2019
- Takeda Launches Zafatek 25 mg for Patients with Renal Dysfunction
December 4, 2019
- Shire Rolls Out Kit Version of Advate IV in Japan
December 4, 2019
- Idelvion’s 3500 IU Vials Available in Japan: CSL Behring
December 4, 2019
- Lenvima’s Add’l Thyroid Cancer Use Accepted for Chinese Regulatory Review
December 3, 2019
- Zykadia’s Film-Coated Tablets Now Available
December 3, 2019
- Full Showdown Starts as Mylan’s Nesp Biosimilar Reaches Market
December 3, 2019
- Crysvita’s Japan Launch Set for Dec. 6: Kyowa Kirin
December 3, 2019
- Chugai Completes Transfer of 3 Dermatology Products to Maruho
December 3, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…